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Abstract
Introduction: Mesenchymal stem cells (MSC) are well described for their role in tissue regeneration following
injury. Migratory properties of endogenous or administrated MSC are critical for tissue repair processes. Platelet-derived
growth factor (PDGF) is a chemotactic growth factor that elicits mesenchymal cell migration. However, it is yet to be
elucidated if signaling pathways other than direct activation of PDGF receptor (PDGF-R) are involved in PDGF-induced
cell migration.
Methods: Knocking down and co-immunoprecipitation approaches were used to evaluate urokinase-type
plasminogen activator receptor (uPAR) requirement and its interactions with proteins involved in migration
mechanisms, in human MSC induced to migrate under PDGF-AB effect.
Results: We demonstrated that uPAR activation and its association with β1-integrin are required for PDGF-AB-induced
migration. This phenomenon takes place in MSC derived from bone marrow and from adipose tissue.
Conclusions: We showed that PDGF-AB downstream signaling requires other effector molecules in MSC such as the
uPA/uPAR system and β1 integrin signaling pathway known for their role in migration. These findings provide new
insights in molecular mechanisms of PDGF-AB-induced migration of human MSC that may be relevant to control MSC
function and tissue remodeling after injury.
Introduction
Mesenchymal stem cells (MSC) were first identified in
bone marrow as a population of plastic adherent and
highly proliferative cells that were able to form colonies
of fibroblasts (colony-forming unit-fibroblasts) [1] and
display multipotency towards multiple lineages in vitro
and in vivo upon transplantation (cartilage, bone, fat,
vascular tissue, and muscle) [2, 3]. Moreover, bone mar-
row mesenchymal stem cells (BM-MSC) show potent
trophic and immunomodulatory functions that promote
tissue repair [4–7]. Nevertheless, the ability of locally
injected or mobilized MSC to migrate in vivo to the sites
of injury remains a critical step. Several studies have
demonstrated the homing of administered MSC to sites
of injury [8, 9]; the migration of MSC to such sites may
be dependent on chemotactic signals derived from
injured or inflamed tissues. A large range of factors exert
chemotactic effects on MSC including inflammatory
cytokines such as interleukin (IL)-1β and tumor necrosis
factor alpha (TNFα) and growth factors [10–12] that can
have additive effects [12]. The platelet-derived growth
factors (PDGFs) are released following platelet aggrega-
tion early after tissue injury and during the inflammatory
process [13]. Numerous studies have demonstrated an
important role for these factors in migration, extracellular
matrix (ECM) synthesis, and proliferation of mesen-
chymal cells, making them key regulatory molecules of
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tissue repair [14], but Ponte et al. [12] showed that TNFα
does not enhance MSC migration towards PDGF. In both
mouse and human, the PDGFs consist of four inactive
monomeric ligands (A–D) that assemble into biologically
active homodimers; only PDGF-A and PDGF-B can
form functional heterodimers. Although PDGF-AA and
PDGF-BB cell signaling has been well described on mi-
gration of cells of mesenchymal origin [14, 15], less is
known about the effects of PDGF-AB. The PDGF-AB
heterodimer has been identified in platelets and may be
specific to humans. Cell stimulation with PDGF-AB
leads to preferential formation of heterodimer receptors
(PDGFR-αβ) and increases its mitogenicity compared
with PDGF-AA or PDGF-BB. The PDGF-AB heterodimer
is thus endowed with different signaling properties from
the homodimers (for review see [16]). PDGF-AB was also
shown to promote human MSC migration [12, 17], but
many questions related to the molecular mechanisms
underlying its effects remain largely unanswered.
The receptor of the urokinase-type plasminogen activa-
tor (uPA) serine protease is present on the surface of
many cell types, including myeloid cells, endothelial cells,
epithelial cells, and vascular smooth muscle cells
(VSMC). Initially described as regulating hemostasis
[18], urokinase-type plasminogen activator receptor
(uPAR) has since been shown to be overexpressed upon
cell exposure to inflammatory mediators and to play a
critical role in the regulation of various cell properties,
especially cell migration (for review see [19]). Indeed,
numerous studies reported that the receptor strongly
contributes to tumor invasiveness (for review see [20])
and VSMC migration [21–25], and Carlin et al. [26]
found that uPA and PDGF have an additive effect on
airway smooth muscle cell migration. Recently, it was
shown that uPA/uPAR also plays a pivotal role in regu-
lating migration and differentiation of MSC [27–31].
Vallabhaneni et al. [29] demonstrated the involvement of
uPAR in mobilization of MSC from mouse bone marrow
as well as uPAR requirement for engraftment of injected
human BM-MSC to the vessel wall of injured mouse fem-
oral arteries. uPAR modulates migration through cooper-
ation between extracellular proteolysis and intracellular
signaling. The human uPAR protein displays three extra-
cellular domains. The amino-terminal domain (D1) con-
tains the main binding site for uPA. Once bound, uPA
catalyzes the conversion of plasminogen into plasmin that
activates several matrix metalloproteinases, thus promot-
ing localized ECM degradation including fibronectin and
vitronectin. Independently of its extracellular proteolytic
role, uPA/uPAR regulates cell migration through activation
of intracellular signaling pathways. uPAR is associated with
the plasma membrane by a glycosyl-phosphatidylinositol
anchor but lacks cytoplasmic domains. Consequently, it
requires transmembrane coreceptors for intracellular
signaling. The ECM protein receptors integrins are the
most important transmembrane partners physically and
functionally associated with uPAR able to connect
uPAR to intracellular signaling pathways [32]. Interest-
ingly, it has recently been shown that integrins are highly
expressed on MSC and that β1 integrin is the most abun-
dant β integrin on the surface of MSC [33, 34].
In this work, we provide evidence that PDGF-AB trig-
gers human BM-MSC migration by recruiting uPAR and
β1 integrins, thus promoting their colocalization at the
cell surface and driving promigratory signaling pathways.
Moreover, we show that this regulatory system is not re-
stricted to MSC purified from human bone marrow but
also triggers migration of an additional MSC cell type;
that is, adipose tissue-derived MSC [35].
Methods
In vitro production and characterization of MSC
Human BM-MSC were isolated from bone marrow of
seven healthy donors. Bone marrow was aspirated from
the posterior iliac crest of adults undergoing orthopedic
surgery (Orthopedic Surgery Department, Trousseau
Hospital, Tours, France) after approval from the Medical
Ethics Committee of Tours (“Comité de Protection des
Personnes Tours—CPP Région Centre [Ouest-1]”) and
in accordance with their guidelines. Written informed
consent was obtained from all patients for the use of
their samples. Adipose stem/stromal cells (ASC) were
isolated as described previously [36] from subcutaneous
adipose tissue obtained from nonobese patients under-
going elective abdominal dermolipectomy (Plastic Surgery
Department, Rangueil Hospital, Toulouse, France). No
objection certificates were obtained, according to Bioeth-
ics Law No. 2004–800 of 6 August 2004. These tissue
samples are seen as waste biological samples in France
and do not require informed consent for their use, in
accordance with the French ethical and legal regulations.
Adherent cells were grown in vitro in minimum essen-
tial medium alpha (MEMα; Invitrogen, Cergy-Pontoise,
France) supplemented with 10 % fetal calf serum (FCS;
Perbio, Brébières, France), 2 mM L-glutamine (Invitro-
gen), 100 U/ml penicillin (Invitrogen), 10 μg/ml strepto-
mycin (Invitrogen), 2.5 μg/ml fungizone (Bristol-Myers-
Squibb, Rueil-Malmaison, France) and 1 ng/ml fibroblast
growth factor-2 (FGF-2; R&D Systems, Lille, France) as
described previously [37]. Following passage 1, when
cultured cells achieved 80–90 % confluence, they were
trypsinized as follows: culture medium was removed,
cells were washed twice with 1X phosphate-buffered sa-
line (PBS; Invitrogen) and a solution containing 0.05 %
trypsin and 0.53 mM ethylenediamine tetraacetic acid
(EDTA; Invitrogen) was added. The cells were incubated
at room temperature for 5 minutes, and afterwards tryp-
sin was neutralized by the addition of serum. Cells were
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counted and viability was assessed using Trypan blue.
Flow cytometry analysis indicated that these cells
expressed CD105, CD73, and CD90 and lacked expres-
sion of CD45, CD34, CD11b, CD19, and HLA-DR
(Figure S1A in Additional file 1). As described previously,
these cells displayed multipotent differentiation potential
under standard in vitro differentiation conditions (Figure
S1B in Additional file 1). Detailed protocols for cell differ-
entiation are presented in Additional file 2.
BM-MSC stimulation by inflammatory cytokines and
PDGF-AB
Passage 1 adherent cells were grown for 5–24 hours
(depending on experiments), at 37 °C in serum-free con-
trol medium (RPMI (Invitrogen), 0.25 % bovine serum
albumin (BSA; PAA Laboratories, Velizy-Villacoublay,
France)) or treated with IL-1β (0.2 ng/ml), IL-8 (150 ng/
ml), TNFα (10 ng/ml), or PDGF-AB (50 ng/ml) (R&D
Systems). Cells were dissociated using trypsin–EDTA
solution (Invitrogen) for PCR analysis or Cell Dissociation
Solution (Sigma-Aldrich, St Quentin Fallavier, France) for
flow cytometry and western blot analysis.
Migration assays
Scratch test
Passage 1 BM-MSC and ASC were serum starved by
culturing them in serum-free control medium for 24
hours. Cells were detached and 1 × 105 cells were seeded
in 12-well plates (Corning, Cambridge, MA, USA)
coated or not with 10 μg/ml type I dermal collagen from
human skin (Merck Millipore-Calbiochem, Saint Quentin
en Yvelines, France) or 5 μg/ml human cellular fibronectin
(Sigma-Aldrich, Saint Quentin-Fallavier, France) or
500 ng/ml human vitronectin (BD Biosciences, Le
Pont de Claix, France ). After 2 hours of adherence
at 37 °C, the scratches were performed using P200 pip-
ette tips and pictures were immediately taken (T = 0)
using an inverted microscope (TG2000-S; Nikon, Cham-
pigny sur Marne, France) and a camera (DXM1200F;
Nikon).
The cells were then treated or not with IL-1β (0.2 ng/
ml), IL-8 (150 ng/ml), TNFα (10 ng/ml), or PDGF-AB
(50 ng/ml) at 37 °C. Pictures of scratches were taken
again after 14, 18, and/or 22 hours to visualize the
wound closure. Scratched surfaces were measured using
ImageJ software [38] (National Institute of Health,
Bethesda, MD, USA). Wound closure surfaces were cal-
culated as the scratch surface at T = 0 minus the scratch
surface at T = 22 hours, and results were expressed as
percentages of wound closure (wound closure surface/
scratch surface at T = 0)x 100.
For inhibitory experiments, before adding neutralizing
antibodies, surface uPA was acid-stripped from adherent
BM-MSC by incubation of cells with 0.05 M glycine, 0.1
M NaCl (pH 3.0; 2 minutes at room temperature), neu-
tralized with 0.5 M HEPES, 0.1 M NaCl (pH 7.5), and
washed with RPMI. Cells were then pretreated or not
with 5 μg/ml goat anti-human uPAR (R&D Systems), 1.5
μg/ml mouse anti-human uPA (American Diagnostica,
Neuville sur Oise, France) neutralizing antibodies, or 50
μM integrin blocking peptide β1P1 (NLDSPEGGF; Tebu-
Bio, Le Perray en Yvelines, France) for 30 minutes at 37 °C
along with corresponding controls: IgG1 and the scram-
bled peptide sc β1P1 (EDGLFNPSG; Tebu-Bio). After-
wards, cells were treated or not with 50 ng/ml PDGF-AB.
Pictures of scratches were taken again to visualize wound
closure.
Transwell migration
Detailed protocols are presented in Additional file 2.
Proliferation assay
Detailed protocols are presented in Additional file 2.
Quantitative (real-time) PCR
We quantified uPAR and uPA mRNA in BM-MSC and
ASC treated or not with IL-8, TNFα, or PDGF-AB for 5,
10, or 24 hours. BM-MSC treated with 100 ng/ml phorbol
myristate acetate (PMA; Sigma-Aldrich) for 18 hours at
37 °C were used as a positive control for uPAR and uPA
mRNA expression. Total RNA was isolated using the
RNeasy Kit (Qiagen, Courtaboeuf, France), according to
the manufacturer’s instructions. First-strand cDNA was
synthesized from 1.5–2.0 μg total RNA using the Prime-
Script™ first strand cDNA synthesis Kit (TaKaRa, Saint
Germain en Laye, France). All samples were subjected to
PCR amplification with oligonucleotide primers for uPAR
or uPA and the constitutively expressed gene for GAPDH.
PCR products were fluorescently labeled using the Eva
Green SMX 1000 (Biorad, Marnes La Coquette, France)
and real-time monitoring of PCR products was measured
by fluorescence (SYBR green) with the Light Cycler
(Biorad). Normalization to GAPDH expression and quan-
tification of RT-PCR were performed using Light Cycler
software (Biorad). A significant change in gene expression
after PDGF-AB treatment was considered when results
were concordant in three experiments showing at least a
twofold increase or decrease compared with baseline
values.
The primer sequences used for real-time PCR are
listed in Additional file 2.
Flow cytometry
Detailed protocols are presented in Additional file 2.
Preparation of BM-MSC cellular membranes
BM-MSC grown in serum-free control medium
(RPMI–0.25 % BSA) or treated with PDGF-AB (50 ng/
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ml) were detached and centrifuged for 10 minutes at
400 × g. After washing with ice-cold PBS, the number
and the viability of the cells were estimated with Trypan
blue. Cell pellets were used immediately for preparation
of cellular membranes as described previously [39],
with minor modifications. Briefly, the pellets were
resuspended in ice-cold Dounce buffer (10 mM Tris–HCl,
pH 7.6, 0.5 mMMgCl2, 1 mM phenylmethylsulfonyl fluor-
ide (PMSF; Sigma-Aldrich), protease inhibitor cocktail
(Sigma-Aldrich)) and homogenized using Dounce
homogenizer. Cell suspensions were centrifuged at 4 °C
for 5 minutes at 400 × g to remove the nuclear fraction.
The supernatants were collected and centrifuged at
100,000 × g at 4 °C for 1 hour to isolate the membranes.
BM-MSC cellular membranes were kept at −80 °C until
analysis by western blot and zymography. Total protein
content was measured using the Coo protein assay deter-
mination kit (Uptima, Montluçon, France).
Western blot analysis of BM-MSC cellular membranes
Detailed protocols are presented in Additional file 2.
Zymography of BM-MSC cellular membranes
Detailed protocols are presented in Additional file 2.
Small interfering RNA and cell transfection
Passage 0 BM-MSC and ASC were transfected with small
interfering RNA (siRNA) of either nontargeting control
siRNA (si Neg) or uPAR siRNA (siPLAUR5-6; Qiagen)
using the Amaxa™ Cell Line Nucleofector™ kit V (Lonza,
Levallois-Perret, France) according to the manufacturer’s
recommendations. Then 500,000 cells were suspended in
100 μl Nucleofector® solution (Lonza) and mixed with 1.5
μg siRNA. Samples were transferred into the Nucleofec-
tor® machine and transfected using the T030 transfection
program. Cells were transferred to culture dishes and
grown in expansion medium (MEMα, 10 % FCS, 2 mM L-
glutamine, 100 U/ml penicillin, 10 μg/ml streptomycin,
2.5 μg/ml fungizone, and 1 ng/ml FGF-2) until they
reached 80 % confluence 5 days later.
Confocal fluorescence microscopy
The cellular localization of uPAR, actin-F, phosphory-
lated focal adhesion tyrosine kinase (P-FAK Tyr397), and
β1-integrin subunit on migrating BM-MSC were ana-
lyzed by confocal microscopy. After a 24-hour serum
starvation, cells were detached and seeded in Lab-Tek®
two-chamber slides (Nalge Nunc International, Roches-
ter, NY, USA) coated with 10 μg/ml type I dermal colla-
gen or 5 μg/ml cellular fibronectin. After 2 hours of
adherence, scratches were performed and cells were
grown in serum-free control medium or treated with 50
ng/ml PDGF-AB for 1, 3, or 6 hours.
Immunocytochemistry detection was performed after
fixation with 4 % paraformaldehyde in PBS for 15 mi-
nutes at room temperature. Nonspecific binding sites
were blocked with 5 % normal goat serum and cells were
incubated with an anti-uPAR antibody (10 μg/ml mouse
anti-human uPAR 3936 or polyclonal rabbit anti-human
uPAR 399R; both American Diagnostica) for 1 hour at
room temperature followed respectively by incubation
with Alexa-488-conjugated goat anti-mouse or anti-
rabbit antibody (1:1000; Molecular Probes-Invitrogen,
Cergy Pontoise, France) for 30 minutes. Cells were perme-
abilized with 0.2 % Tween 20 and incubated respectively
with AlexaFluor 594-phalloïdin (1:40; Molecular Probes-
Invitrogen) for 30 minutes or anti P-FAK Tyr397 rabbit
polyclonal antibody (1:50; Santa Cruz Biotechnologies,
Heidelberg, Germany) for 1 hour followed by Alexa-594-
conjugated goat anti-rabbit antibody (1:1000; Molecular
Probes-Invitrogen) for 30 minutes. For β1-integrin
staining, cells were incubated with anti-human integrin
β1 (JB1A, 1:400; Chemicon-Millipore, Guyancourt,
France) mouse antibody for 1 hour followed by Alexa-
594-conjugated goat anti-mouse antibody (1:1000; Mo-
lecular Probes-Invitrogen) for 30 minutes.
Samples were imaged after mounting with Dako mount-
ing medium which stains nuclei with 4′,6-diamidino-2-
phenylindole (DAPI). Confocal microscopy imaging was
performed on an inverted laser-scanning Olympus FV500
microscope (Olympus, Rungis, France ). Images were cap-
tured with a ×60 oil-immersion objective, analyzed with
Olympus software, and were subsequently processed for
analysis using Imaris software (Bitplane AG, Zurich,
Switzerland).
Immunoprecipitation and western blot analysis
To determine uPAR/P-FAK and uPAR/β1 integrin associ-
ations, coimmunoprecipitation experiments were per-
formed. Serum-starved cells were seeded in six-well plates
coated with 10 μg/ml type I dermal collagen or 5 μg/ml
cellular fibronectin. After 2 hours of adherence, cells were
treated or not with 50 ng/ml PDGF-AB for 1, 3, or
18 hours and lysed on ice with RIPA buffer (Santa
Cruz Biotechnologies) supplemented with protease inhibi-
tor cocktail, 2 mM PMSF (Sigma-Aldrich), and phosphat-
ase inhibitor cocktails (Santa Cruz Biotechnologies), at
each time point; that is, before adherence (T0), 2 hours
post adherence (Adh), and following PDGF-AB treatment
(during 1, 3, and 18 hours). The insoluble fraction was
pelleted by centrifugation at 13,000 rpm for 10 minutes at
4 °C and total protein content was measured using the
Coo protein assay determination kit (Uptima).
The supernatants (100 μg proteins) were precleared
with protein A/G Plus agarose beads (Santa Cruz Bio-
technologies) for 2 hours at 4 °C, and then incubated
overnight at 4 °C with antibodies against integrin β1
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(JB1A, 1:1000; Chemicon-Millipore) for β1 integrin/uPAR
coimmunoprecipitation experiments, or uPAR (IID7, 2 μg;
Santa Cruz Biotechnologies) for uPAR/P-FAK coimmuno-
precipitation experiments, or isotypic control IgG. Immu-
noprecipitates were washed with PBS, eluted with
Laemmli sample buffer, resolved by 8 % (for β1 integ-
rin) or 12 % (for uPAR) SDS-PAGE and then blotted
for β1 integrin (1:200; Chemicon-Millipore) and uPAR
(399R, 1:1000; American Diagnostica) or uPAR (399R,
1:1000; American Diagnostica) and P-FAK (1:1000; Invi-
trogen). After being washed, PVDF membranes were in-
cubated with horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG or HRP-conjugated goat anti-rabbit
IgG (1:3000; Biorad). Protein bands were revealed by
chemiluminescence using the ECLplus western blotting
reagent (GE Healthcare Europe GmbH, Aulnay sous
Bois, France) and membranes were analyzed at 430
nm using a camera and the Chemicapt® software (Vilber
Lourmat , Marne la Vallée, France). Bands were quantified
by densitometry analysis using ImageJ software (National
Institute of Health).
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). They were analyzed with GraphPad Prism
5 software (La Jolla, CA, USA ) using the parametric t
test or the nonparametric Mann–Whitney test with the
significance level set at P <0.05.
Fig. 1 Regulation of BM-MSC migration by inflammatory molecules. Scratch test assay was performed on BM-MSC isolated from three different
donors and seeded in plates coated with type I dermal collagen, cellular fibronectin, or vitronectin or without ECM. Pictures of scratches were
taken immediately (T = 0) or 22 hours after culture (T = 22 h) in serum-free control medium or medium supplemented with IL-1β, IL-8, TNFα, or
PDGF-AB. a Quantification of BM-MSC migration. Results expressed as percentages of wound closure at T = 22 h compared with T = 0 for each
condition. Data expressed as mean ± SEM of three independent experiments (one donor per experiment), each performed in triplicate. *P <0.05.
b, c One experiment representative of the three experiments is shown. ECM extracellular matrix, IL interleukin, PDGF-AB platelet-derived growth
factor AB, TNFα tumor necrosis factor alpha
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Results
PDGF-AB enhances BM-MSC migration on type I dermal
collagen, cellular fibronectin, and vitronectin
To investigate which inflammatory molecules play a key
role in BM-MSC migration, we used an in vitro scratch
test assay in which plates were coated or not with three
different ECM proteins overexpressed in wounding tis-
sues including vitronectin, fibronectin, and type I dermal
collagen. In the presence or absence of ECM, nontreated
BM-MSC displayed poor migratory capacities 22 hours
after the scratch (Control; Fig. 1a, b). IL-1β, IL-8, and
TNFα had no effect on BM-MSC migration in the
absence of ECM or on vitronectin, compared with non-
treated BM-MSC (Control; Fig. 1a). IL-1β did not affect
BM-MSC migration in any other conditions tested while
IL-8 stimulated BM-MSC migration on collagen I only
(12 % enhancement) and TNFα increased BM-MSC mi-
gration on fibronectin (13 % enhancement) and collagen
I (10 % enhancement). The effects of IL-8 and TNFα on
BM-MSC migration were far less than those of PDGF-
AB. PDGF-AB significantly enhanced the migration of
BM-MSC; 18 % enhancement in absence of ECM, 22 %
on vitronectin, 36 % on fibronectin, and greater effects
were observed on type I dermal collagen: 43 % enhance-
ment (Fig. 1a, c). As migratory stimulation by PDGF-AB
was observed for the three time points we tested (14, 18,
and 22 hours) (data not shown), all of the following
migration experiments were conducted 22 hours after
scratch. We controlled so that proliferation of BM-MSC
was not increased under any condition used for the
scratch test assay (Figure S2A in Additional file 3). The
effect of PDGF treatment on stimulation of MSC migra-
tion was confirmed using another migration assay, in
transwell dishes (Figure S2B in Additional file 3). The
results showed that PDGF-AB treatment for 22 hours
increased by sixfold the number of cells that migrated
on the lower face of the filters. These results indicate
that BM-MSC migrate in response to several mole-
cules known to be released in damaged tissue and that
PDGF-AB is one of the most potent, especially on col-
lagen I.
PDGF-AB stimulates uPAR and uPA expression in BM-MSC
To examine whether uPAR was involved in PDGF-AB-
induced migratory capacities, we first quantified uPAR
gene expression in BM-MSC and its regulation by
PDGF-AB. Kinetic experiments revealed that uPAR
mRNA levels reached a twofold increase after treatment
with PDGF-AB as soon as 5 hours post treatment
(Fig. 2a). At the protein level, both flow cytometry ana-
lysis on intact cells and western blotting on isolated cell
membrane fractions revealed that control BM-MSC
weakly expressed uPAR at their surface, whereas 24
hours post PDGF-AB treatment the cell surface
expression of uPAR was significantly increased (Fig. 2b,
c), indicating that mRNA and protein expressions are
regulated in a similar manner. Three major isoforms of
uPAR were detected in BM-MSC cellular membranes at
55, 45, and 40 kDa and each isoform’s expression was
increased by the PDGF-AB treatment (Fig. 2c).
Because uPAR could be activated in an autocrine man-
ner, we examined the effect of PDGF-AB on uPA mRNA
gene expression in BM-MSC. In basal conditions, control
MSC expressed high mRNA levels of uPA (data not
shown). Following PDGF-AB treatment, uPA mRNA con-
tent tended to be upregulated at 10 hours post treatment
and decreased after 24 hours (Fig. 2d). As shown in Fig. 2e,
uPA was weakly detected by western blotting on cell
membrane fraction of control BM-MSC, while three
major bands of membrane-bound uPA (54, 52, and 49
kDa) were increased after 24 hours of PDGF-AB treat-
ment. Zymographic analysis of the BM-MSC cell mem-
brane fraction (Fig. 2f) confirmed that the 52 and 49 kDa
bands were the active forms of uPA while there was no
band detected at 54 kDa. These results highlight an activa-
tion of the uPA/uPAR system after PDGF-AB treatment.
As IL-8 and TNFα induced BM-MSC migration (although
to a lesser extent than PDGF-AB), uPA and uPAR gene
expression were also assessed under IL-8 and TNFα treat-
ment (Additional file 4). IL-8 did not affect uPAR or uPA
gene expression. While TNFα enhanced uPAR gene ex-
pression after 24 hours of treatment (twofold increase), it
strongly decreased uPA gene expression (more than 70 %
reduction) compared with nontreated control condi-
tions. These results suggest that IL-8 and TNFα stimulate
BM-MSC migration via a signaling pathway that does not
involve uPA.
The uPA/uPAR system is required for PDGF-AB-induced
BM-MSC migration
As PDGF-AB stimulated both uPA and uPAR expression
and BM-MSC migration in vitro, we tested whether these
proteins were required for PDGF-AB-induced BM-MSC
migration using two loss-of-function strategies. We first
investigated the effect of neutralizing anti-uPAR anti-
bodies in a scratch test assay. Neutralizing antibodies
displayed no effect on BM-MSC basal migration but sig-
nificantly decreased the capacity of PDGF-AB-treated
BM-MSC to reconstitute the scratched area (Fig. 3a, b).
The same results were obtained using anti-uPA anti-
bodies (Fig. 3a, b) independently of the matrix tested
(Additional file 5). To confirm these results, we used
a siRNA to reduce uPAR expression in BM-MSC and
the scratch test assay was performed on type I dermal
collagen. BM-MSC were transfected with control siRNA
(si Neg) or uPAR targeted siRNA (si uPAR) and the
knocking down efficiency was evaluated by quantitative
PCR and flow cytometry approaches. A 77 % decrease in
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Fig. 2 (See legend on next page.)
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Fig. 3 uPA/uPAR mediate PDGF-AB-induced BM-MSC migration. a, b Scratch test assay was performed on BM-MSC isolated from three different
donors and seeded in plates coated with type I dermal collagen. Pictures of scratches were taken immediately (T = 0) or 22 hours after
culture (T = 22 h) in serum-free control medium or PDGF-AB supplemented medium in the presence or not of anti-uPAR or anti-uPA
neutralizing antibodies. a An experiment representative of three experiments. b Quantification of BM-MSC migration. c, d Scratch test
assay was performed on BM-MSC isolated from three different donors transfected with either control siRNA (si Neg) or uPAR siRNA (si uPAR) and
grown on type I dermal collagen in serum-free control medium or treated with PDGF-AB. c An experiment representative of three
experiments. d Migration quantification of transfected BM-MSC. b, d Results expressed as percentages of wound closure at T = 22 h
compared with T = 0. Mean of three independent experiments ± SEM are represented (one donor per experiment), each performed in
triplicate. *P <0.05. Scale bars: 200 μm. PDGF-AB platelet-derived growth factor AB, si Neg nontargeting small interfering RNA, si uPAR
uPAR-targeted small interfering RNA, uPA urokinase-type plasminogen activator, uPAR urokinase-type plasminogen activator receptor
(See figure on previous page.)
Fig. 2 PDGF-AB regulates uPAR and uPA expression in BM-MSC. BM-MSC were grown in serum-free control medium or treated with PDGF-AB. a Quantitative
PCR analysis of uPAR mRNA synthesis 5, 10, or 24 hours after treatment. Data from four donors are presented as the uPAR mRNA fold change relative to
nonstimulated control cells for each donor (1 = no stimulation). b Flow cytometry analysis of uPAR cell surface expression; 24 hours after treatment, cells were
stained with anti-uPAR monoclonal antibody (dark curves) or its isotypic control (grey curves). One representative experiment of one donor of the five assessed
is shown (left). Quantification data (right) expressed as mean ± SEM of uPAR fluorescence intensity relative to the isotype of five independent experiments
(one donor per experiment). *P <0.05. c Western blot analysis of uPAR in cellular membranes 24 hours after treatment.***P <0.001 d Quantitative PCR
analysis of uPA mRNA synthesis 5, 10, or 24 hours after treatment. Data from four donors are presented as uPA mRNA fold change relative to nonstimulated
control cells for each donor (1 = no stimulation). eWestern blot analysis of uPA in cellular membranes 24 hours after treatment. f Zymographic analysis of
uPA activity in cellular membranes 24 hours after treatment. Purified high molecular weight human urokinase was used as standard (ST). c, e, f (left) Data
represent one representative experiment, (right) bands were quantified by densitometry analysis using ImageJ software, normalized to β-actin (c, e). Data
expressed as mean ± SEM of three to five independent experiments (one donor per experiment). MFI mean fluorescence intensity, PDGF-AB platelet-derived
growth factor AB, PE phycoerythrin, uPA urokinase-type plasminogen activator, uPAR urokinase-type plasminogen activator receptor
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Fig. 4 (See legend on next page.)
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uPAR mRNA expression and a 90 % decrease in
uPAR protein synthesis were observed (Figure S5A, B
in Additional file 6). BM-MSC wound closure capacity
was increased by 29 % after 22 hours of treatment with
PDGF-AB and this effect was inhibited when BM-MSC
were transfected with uPAR siRNA (Fig. 3c, d). On trans-
well dishes, the effect of PDGF-AB was significantly
reduced by uPAR siRNA (81 % reduction) (Figure S5C in
Additional file 6). All together these results demonstrate
that uPAR is required for PDGF-AB-induced migration of
BM-MSC.
PDGF-AB enhances migration of BM-MSC through control
of uPAR and β1-integrin association
We tested whether PDGF-AB promotes the association
of uPAR with β1 integrin in BM-MSC. We first exam-
ined the localization of uPAR using confocal microscopy
and its interaction with the cytoskeleton in migrating
cells. BM-MSC underwent scratch and they were treated
or not with PDGF-AB. uPAR and phalloidin stainings
were performed 6 hours after the scratch (this is the time
at which cell migration, cytoskeleton remodeling, and la-
mellipodia extension begin). Immunofluorescence analysis
revealed that in resting cells uPAR was uniformly distrib-
uted on the cell surface and dispersed as small aggregates.
In migrating cells, PDGF-AB treatment strongly modified
cell morphology and uPAR distribution, with a clustering
of uPAR at the leading edge of the cells in focal adhesions
(Additional file 7). We next examined the distribution of
uPAR and β1 integrin on migrating cells induced by
PDGF-AB. Because uPAR staining appeared to be par-
tially co-localized with β1 integrin as soon as 1 hour
after PDGF-AB treatment of BM-MSC plated on type
I dermal collagen (Fig. 4a) and on fibronectin (Figure
S7A in Additional file 8), we used coimmunoprecipitation
experiments to determine whether uPAR and β1 integrin
were physically associated. Results shown in Fig. 4b dem-
onstrated that the antibodies against the β1-integrin sub-
unit (but not the control IgG) precipitated not only the
β1-integrin subunit but also uPAR in nontreated cells,
suggesting a physical association between uPAR and the
β1-integrin subunit. The quantity of coimmunoprecipi-
tated β1 integrin and uPAR was increased 1 and 3 hours
post PDGF-AB treatment. The same trend was obtained
at 3 hours on fibronectin (Figure S7B in Additional file 8).
To evaluate whether the physical association of uPAR
with β1 integrin was involved in PDGF-AB-induced cell
migration, we performed a scratch assay on control or
PDGF-AB-treated BM-MSC using β1P1 peptide that
acts as a competitive inhibitor of β1 integrin. Results in
Fig. 4c showed that β1P1, as well as anti-uPAR neutraliz-
ing antibodies, blocked PDGF-AB-induced wound clos-
ure by cells seeded on type I dermal collagen. The same
results were obtained when the cells were seeded on
fibronectin but not on vitronectin (Additional file 9). The
scrambled control peptide had no effect independently of
the matrix used. Taken together, these data demonstrate
that PDGF-AB enhances uPAR interaction with β1 integ-
rin to promote BM-MSC migration on dermal collagen
and fibronectin but not on vitronectin.
PDGF-AB increases the interaction of uPAR with the β1-
integrin signaling pathway
The focal adhesion tyrosine kinase (FAK), when autop-
hosphorylated at Tyr397 (P-FAK), is known to be
involved in the β1-integrin signaling pathway induced by
uPAR. We thus examined uPAR and P-FAK expression
in migrating cells on type I dermal collagen in response to
PDGF-AB treatment. As for uPAR, P-FAK immunofluor-
escent staining was poorly detected in resting control
cells, while it was clearly enhanced in PDGF-AB-induced
migrating cells (Fig. 5a). To assess whether uPAR and
P-FAK were physically associated in focal complexes,
coimmunoprecipitation experiments were performed on
cell lysates from BM-MSC induced to migrate on type I
dermal collagen. As shown in Fig. 5b, the anti-uPAR anti-
bodies (but not the control IgG) immunoprecipitated
uPAR isoforms as well as P-FAK in nontreated cells,
(See figure on previous page.)
Fig. 4 PDGF-AB enhances migration of BM-MSC through control of uPAR and β1-integrin association. a uPAR (green) and β1-integrin subunit
(red) repartition in migrating cells. Images were acquired with a confocal microscope. uPAR and β1-integrin stainings were merged to
show colocalization (yellow). Nuclei were stained with DAPI. Scale bars: 10 μm. b uPAR-β1 subunit coimmunoprecipitation. Two hours after
adherence (Adh) on type I dermal collagen, cells were grown in serum-free control medium (−) or treated with PDGF-AB (+) for 1–18 hours. β1 integrin
was immunoprecipitated from cell lysates with anti-β1 monoclonal antibodies or isotypic control IgG1. Immunoprecipitates were analyzed
by SDS-PAGE and blotted for β1-integrin subunit (top western blot) and uPAR (bottom western blot). (Left) Western blot representative of
three experiments. T0, lysate of cells before seeding; Adh., lysate of cells allowed to adhere for 2 hours on type I dermal collagen. (Right)
uPAR blots quantification by densitometry analysis using ImageJ software. Data expressed as the uPAR fold change after PDGF-AB treatment compared
with serum-free control medium from three independent experiments (one donor per experiment). c Scratch test assay was performed on BM-MSC
isolated from three different donors and seeded in plates coated with type I dermal collagen. Two hours after adherence, cells were
grown in serum-free control medium or treated with PDGF-AB, supplemented or not with integrin blocking peptide β1P1 along with the
corresponding scrambled control scβ1P1 or anti-uPAR neutralizing antibody. Results are expressed as percentages of wound closure at T = 22 h compared
with T = 0. Mean of three independent experiments ± SEM are represented (one donor per experiment), each performed in triplicate. *P <0.05. PDGF-AB
platelet-derived growth factor AB, uPAR urokinase-type plasminogen activator receptor
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suggesting a physical association between uPAR and P-
FAK. This effect appeared to take place as soon as the
cells adhered to the coated plastic and was enhanced after
1 hour of treatment with PDGF-AB.
The PDGF-AB effect is not restricted to MSC derived from
bone marrow
We wondered whether uPAR was required for migra-
tion of MSC from other tissue origin such as ASC
that can be isolated from adipose tissue. Migration assays
were performed following PDGF-AB treatment and uPAR
gene expression knockdown. ASC were transfected with
control siRNA (si Neg) or uPAR targeted siRNA (si uPAR)
and the knockdown efficiency was confirmed by quantita-
tive RT-PCR and flow cytometry experiments that indi-
cated, respectively, a 60 % decrease in uPAR mRNA
expression (Figure S9A in Additional file 10) and a 90 %
decrease in uPAR membrane protein expression (Figure
S9B in Additional file 10). The scratch test assay was then
conducted on type I dermal collagen in the presence or
not of PDGF-AB. ASC migration showed a 30 % increase
after 22 hours of treatment with PDGF-AB (Fig. 6a, b),
while this increase observed under PDGF-AB treatment
was inhibited when ASC were transfected with uPAR
siRNA. On transwell dishes, PDGF-AB enhanced by
sevenfold the number of migrated ASC and this effect was
Fig. 5 PDGF-AB enhances uPAR/P-FAK interactions in migrating BM-MSC. a uPAR (green) and P-FAK (red) repartition in migrating cells. BM-MSC
were seeded in a Labtek chamber coated with type I dermal collagen. After the scratch was performed, cells were grown in serum-free control
medium or treated with PDGF-AB for 3 hours. uPAR and P-FAK stainings were merged to show colocalization (yellow). Nuclei were stained with
DAPI. Scale bars: 10 μm. b uPAR–P-FAK coimmunoprecipitation. Two hours after adherence on type I dermal collagen, cells were seeded in
serum-free control medium (−) or treated with PDGF-AB (+) for 1 hour. uPAR was immunoprecipitated from cell lysates with anti-uPAR monoclonal
antibodies or isotypic control IgG1. Immunoprecipitates were analyzed by SDS-PAGE and blotted for uPAR and P-FAK. (Left) Western blot representative
of three experiments. T0, lysate of cells before seeding; Adh., lysate of cells allowed to adhere for 2 hours on type I dermal collagen. (Right) P-FAK blots
quantification by densitometry analysis using ImageJ software. Data expressed as the P-FAK fold change after PDGF-AB treatment compared with
serum-free control medium from three independent experiments (one donor per experiment). PDGF-AB platelet-derived growth factor AB, P-FAK
autophosphorylated focal adhesion tyrosine kinase, uPAR urokinase-type plasminogen activator receptor
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significantly reduced by uPAR siRNA (52 % reduction)
(Figure S9C in Additional file 10). Similar results were thus
obtained with ASC and BM-MSC, showing that PDGF-AB
increased ASC migration on type I dermal collagen and that
this effect was partially abrogated by knocking down uPAR
gene expression. These results demonstrated that uPAR is
required for PDGF-AB-induced migration of MSC from
different tissue origin (bone marrow and adipose tissue).
Discussion
In response to inflammatory cytokines and growth fac-
tors that are released upon tissue injury, endogenous
and grafted exogenous MSC have the potential to mi-
grate towards the damaged areas and improve tissue
regeneration. Among chemotactic factors, PDGFs are
known to increase MSC migration through PDGF recep-
tors (PDGFRs) [12, 40–42] but their effects are also
mediated by different proteins such as thrombospontin
that has been reported to be an important mediator of
PDGF-DD-stimulated migration of retinal pericytes [14]
and neuropilin-1 that has been shown to associate with
PDGFRs signaling in the presence of PDGF-AA or
PDGF-BB, thereby regulating MSC migration in a ligand-
specific manner [43]. In the present study, we exam-
ined whether the uPA/uPAR system was involved in
PDGF-AB-induced human MSC migration. First, we
showed clear effects of PDGF-AB treatment on uPA and
uPAR protein upregulation and activation in migrating
human BM-MSC. Then, loss-of-function experiments
using specific blocking antibodies and siRNA oligonucleo-
tides provided strong evidence that the uPA/uPAR system
is required for PDGF-AB to control migration of human
MSC. Coimmunoprecipitation experiments confirmed
that uPAR activation following PDGF-AB stimulation trig-
gered uPAR downstream signaling, namely β1 integrin
and FAK, an integrin-associated signaling molecule that
plays a selective role in the regulation of cell migration
induced by uPAR/β1 integrin [44–46]. In vascular smooth
muscle cells, interplays between PDGF and the uPA/uPAR
axis have been reported previously by Kiyan et al. [23],
who demonstrated that uPA-induced migration signal-
ing was transmitted through PDGFRs. The authors
highlighted an association between the uPAR and
PDGFRβ receptors induced by uPA stimulation. Previ-
ous data from Stepanova et al. [47] on smooth muscle
cells described that PDGF-BB-induced cell migration
required uPA, without demonstrating involvement of
uPAR intracellular signaling, while Reuning et al. [48]
demonstrated an increase in uPAR mRNA expression
upon PDGF-BB treatment. Our data add new insights
to these findings and provide evidence that PDGF
downstream signaling involves the uPA/uPAR intracel-
lular signaling in migrating MSC. Our results were ob-
tained on dermal collagen and fibronectin but not on
Fig. 6 ASC migration is mediated by uPAR. a Scratch test assay was performed on ASC isolated from three different donors transfected with
either si Neg or si uPAR and grown on type I dermal collagen in serum-free control medium or PDGF-AB-supplemented medium. Scale bars: 200
μm. b Quantification of ASC migration. Results expressed as percentages of wound closure at T = 22 h compared with T = 0 for each condition.
Mean of three independent experiments ± SEM is represented (one donor per experiment), each performed in triplicate. *P <0.05. ASC adipose
stem/stromal cells, si Neg nontargeting small interfering RNA, si uPAR uPAR-targeted small interfering RNA, PDGF-AB platelet-derived growth
factor AB
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vitronectin, which is in agreement with Madsen et al.
[49], who reported that uPAR can bind directly its two
extracellular domains D2D3 to the glycoprotein vitro
nectin and that cell migration on vitronectin is posi-
tively regulated by uPA but does not require physical
interaction between uPAR and β1 integrins.
The uPA/uPAR system is an ancient, highly conserved
system that is crucial for many cell functions such as
hemostasis, cell motility, invasion, proliferation, and sur-
vival. In the context of MSC engraftment or mobilization
following tissue injury, MSC migration would be under the
control of a stimulated autocrine loop involving uPAR.
Supported by our complementary technical approaches on
MSC from two different tissue origins, we propose that
when vascular injuries that are associated with tissue
lesions occurred, PDGF that is released from platelets and
monocytes [50] would stimulate an autocrine loop that in-
duces uPA increased expression and uPAR activation by
uPA in MSCs. Activated uPAR would associate with β1 in-
tegrin and activate FAK signaling, thus triggering human
MSC migration to the site of injury. This regulatory system
of migration would be common to human bone marrow
and adipose tissue mesenchymal cells. Other extracellular
molecules such as vitronectin and the cleaved high mo-
lecular mass kininogen can bind to uPAR [32]; thus, it
would be interesting to investigate whether PDGF-AB
binds directly to uPAR or not. Supporting this hypothesis
in another signaling system, Ball et al. [51] reported that
vascular endothelial growth factor A (VEGF-A) could dir-
ectly signal through PDGFRs to regulate human MSC mi-
gration. Elsewhere, we could consider that PDGF-AB may
induce a cross-talk between PDGFRs and uPAR, leading
to increased cell migration; in the same way as Kiyan et al.
[23] highlighted an association of uPAR with PDGFRβ in
an uPA-dependent manner.
Conclusions
Our findings demonstrate a functional link between
PDGF and the nonproteolytic uPAR signaling cascade
that regulates human MSC migration. These findings
provide new insights into the molecular basis of the
PDGF-induced signaling mechanisms in human MSC
for tissue remodeling.
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